Compare Medpace Holdings Inc (MEDP) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs NIO Inc. — how do they compare? Medpace Holdings Inc trades at $530.58 (market cap $15.08B), while NIO Inc. trades at $4.89 (market cap $12.55B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| MEDP | NIO | |
|---|---|---|
Market Cap | $15.08B | $12.55B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $7.89 |
52-Week Low | $308.88 | $4.44 |
Enterprise Value | $14.55B | $11.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
NIO trades at $4.83, down 1.02% on the day, with a bearish technical signal from moving averages. Revenue grew to $87.49B in 2025, but the company posted a net loss of $15.57B, reflecting persistent profitability challenges. Recent news highlights strong Q2 2026 vehicle deliveries, up 49.4% year-over-year, and a Goldman Sachs upgrade to Buy with a $7 price target, suggesting potential upside.
The outlook remains mixed: delivery growth and analyst optimism contrast with deep losses and negative cash flow. Key risks include intense EV competition and reliance on financing. Investors should weigh the growth trajectory against the path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
